International Stem Cell (OTCMKTS:ISCO) Posts Earnings Results

International Stem Cell (OTCMKTS:ISCO) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.03) EPS for the quarter, Zacks reports.

International Stem Cell Stock Performance

Shares of ISCO remained flat at $0.18 during trading hours on Thursday. 4,607 shares of the company were exchanged, compared to its average volume of 2,015. International Stem Cell has a 1-year low of $0.11 and a 1-year high of $0.27. The company’s 50 day moving average is $0.16 and its 200-day moving average is $0.15. The company has a market cap of $1.41 million, a P/E ratio of -2.95 and a beta of 0.06.

International Stem Cell Company Profile

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.